92223-80-8

Basic information

• Product Name: Tert-Butyl Oxirane-2-Carboxylate
• Synonyms: Tert-Butyl Oxirane-2-Carboxylate
• CAS NO: 92223-80-8
• Molecular Formula: C₇H₁₂O₃
• Molecular Weight: 144.16838
• Mol File: 92223-80-8.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Tert-Butyl Oxirane-2-Carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Tert-Butyl Oxirane-2-Carboxylate(92223-80-8)
• EPA Substance Registry System: Tert-Butyl Oxirane-2-Carboxylate(92223-80-8)

Safety Data

• Hazardous Substances Data: 92223-80-8(Hazardous Substances Data)

Upstream product

• 75-91-2 tert.-butylhydroperoxide 
• 141-32-2 acrylic acid n-butyl ester 
• 109-72-8 n-butyllithium 
• 292638-85-8 acrylic acid methyl ester 
• 1663-39-4 tert-Butyl acrylate 

Relevant articles and documents

SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME

The present disclosure relates to compounds of Formula (I): (I); and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.

BICYCLIC ARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS

The present invention relates to bicyclic aryl monobactam compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A1, L, M, W, X, Y, Z, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a bicyclic aryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of one or more beta-lactamase inhibitor compounds.

The crystal structure of an LLL-configured depsipeptide substrate analogue bound to isopenicillin N synthase

Isopenicillin N synthase (IPNS) is a non-heme iron(II) oxidase, which catalyses the biosynthesis of isopenicillin N (IPN) from the tripeptide δ-L-α-aminoadipoyl-L-cysteinyl-D-valine (LLD-ACV) in a remarkable oxidative bicyclisation reaction. The natural substrate for IPNS is the LLD-configured tripeptide. LLL-ACV is not turned over by the enzyme, but inhibits turnover of the LLD-tripeptide. The mechanism by which this inhibition takes place is not fully understood. Recent studies have employed a range of LLD-configured depsipeptide substrate analogues in crystallographic studies to probe events preceding β-lactam closure in the IPNS reaction cycle. Herein, we report the first crystal structure of IPNS in complex with an LLL-configured depsipeptide analogue, δ-L-α-aminoadipoyl-L-cysteine (1-(-R)-carboxy-2-thiomethyl)ethyl ester (LLL-ACOmC). This report describes the crystal structure of the IPNS:Fe(II):LLL-ACOmC complex to 2.0 A resolution, and discusses attempts to oxygenate this complex at high pressure in order to probe the mechanism by which LLL-configured substrates inhibit IPNS catalysis. The Royal Society of Chemistry 2010.